Executive Management Team
Chief Executive Officer
Mr. Heydler was President and CEO at Barcelona Design Inc. based in San Jose, USA. Before joining Barcelona, Mr. Heydler served as President and CEO for InterPro Business Solutions, Inc., USA. He was Vice President and Executive Officer at Documentum Inc., a leading software and solutions provider with specific focus on the pharmaceutical and life sciences industry.
He built and drove Documentum’s European operations and assumed worldwide responsibility for Marketing and Documentum’s Application Business subsequently. Prior to this engagement, he served as Vice President and General Manager Europe for Cadence Design Systems and held senior leadership positions at Siemens AG.
Mr. Heydler holds a Diplom-Ingenieur degree in Electric Engineering and Computer Science from the Technical University in Munich.
Chief Operating Officer
In his previous role as CEO of Holtzbrinck Digital, he was responsible for the global digital and technology portfolio of the Holtzbrinck Group. During that time, he gained a broad sector experience in the direct-to-consumer internet market establishing market leaders in Germany as well as in SaaS business with a focus on the science, medicine, and education segments operating globally.
Under his leadership, successful exits like Parship dating app had a vital contribution to the shareholder value of the Holtzbrinck Group. Furthermore, the Digital Science portfolio - a carve out of the Nature Publishing Group – became one of the fastest growing activities under his responsibility.
During his career, Markus held several senior positions in general management in the role as CFO and served as a member of the Board for more than 30 companies.
Markus holds a Masters of Business Administration (Diplom-Kaufmann) from the University of Tübingen (DE).
Chief Strategy and Corporate Development Officer
Markus Rinecker, MD
Prior to joining Definiens, Dr. Rinecker served as Managing Director at one of the leading surgical hospitals in Munich. While managing 350 employees with full P&L responsibility, he established a new department for open heart surgery and streamlined organizational processes to increase the organization’s profitabiligy. For the hospital chain Humaine Kliniken GmbH he evaluated potential acquisition targets and participated in multiple share deal transactions. He was also actively involved in the start-up venture ProHealth AG, which opened Europe’s first full clinical proton radiation center for cancer therapy, in March 2009.
Dr. Rinecker holds a Doctoral Degree in Medicine at the Ludwig-Maximilians-University in Munich as well as a Masters Degree in Business Administration of INSEAD, France and Singapore.
Chief Medical Officer
Ralf Huss, MD
Dr. Huss is a board-certified surgical and molecular pathologist and obtained his medical doctorate from the Universität Erlangen (DE) in 1991. He is specialized in internal medicine (Universitätsspital Zürich (CH)) and immunology (Institut für Pathologie under Nobel Laureate Rolf M. Zinkernagel), Universität Zürich (CH). Also, Huss is an Associate Professor at Ludwigs-Maximilians-Universität München (DE), a lecturer at the Technische Universität München, and honorary professor at the School of Medicine, University College Dublin (IE).
Dr. Huss spent his early career during the 1990s as a Research Associate in Nobel laureate Edward D. Thomas’ Laboratory at the Fred Hutchinson Cancer Research Center, in Seattle, Washington (US). Later, he returned to Europe to become an immunology researcher at the Institut für Immunologie, Universitätsklinikum Essen (DE) and completed his pathology training at the Ludwig-Maximilians-University München (Institut für Pathologie) between 1995 and 2005.
In 2005, he joined Roche Diagnostics as Global Head of Pathology and Tissue Biomarkers and later headed the Cell Therapy Initiative at Roche Penzberg (DE). In 2011, he joined apceth GmbH, a stem-cell and gene-therapy company which he co-founded in München, as Chief Scientific Officer, where he worked until starting at Definiens in 2015.
Scientific Advisory Board
Scientific Advisory Board
Dr. Gerd Binnig founded Definiens with the goal to transform the image analysis industry by enabling more data to be extracted for better decisions. Dr. Binnig, along with his colleague Dr. Heinrich Rohrer, was awarded the Nobel Prize for Physics in 1986.
Manfred Dietel, MD
Dr. Manfred Dietel is Director, Institute of Pathology, Campus Charitè-Mitte. He is also a Member of the Board of Directors of the Association of German University Hospitals and a Member of the Board of Directors of the German Society of Pathology.
Bernard Fox, PhD
Dr. Fox is the Harder Family Chair for Cancer Research, Member and Chief of the Laboratory of Molecular and Tumor Immunology at the Earle A. Chiles Research Institute, Robert W. Franz Cancer Center and Providence Cancer Institute in Portland, Oregon, USA. He is also the CEO of UbiVac, a company he founded to move disruptive immunotherapies to the clinic. A past President of SITC and Chair of WIC, he is active in the international immunotherapy community.
Ben Glocker, PhD
Ben Glocker is Senior Lecturer in Medical Image Computing at Imperial College London and one of three academics leading the Biomedical Image Analysis Group. He holds a PhD from TU Munich, and was a post-doc at Microsoft and a Research Fellow at the University of Cambridge. His research focuses on machine learning and artificial intelligence for medical imaging with various clinical applications including trauma, oncology and population health.
James L. Gulley, MD, PhD, F.A.C.P.
Dr. Gulley is Director of the Medical Oncology Service, Chief of the Genitourinary Malignancies Branch and Head of the Immunotherapy Section at NCI. He is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. He serves as the principal investigator on several international clinical trials, among which for a prostate cancer vaccine and several trials using immune checkpoint inhibitors.
David Harrison, MD
David Harrison is Professor of Pathology, and Director of Research, in the School of Medicine, University of St Andrews, Scotland. He holds honorary positions in Universities of Edinburgh and Florida. He is also Director of Development for Laboratory Medicine for the Edinburgh University Hospitals. He chairs the UK government Committee on Carcinogenicity.
Ronald Herbst, PhD
Dr. Ronald Herbst is Vice President of Research and Development and Head of Oncology Research for MedImmune. In this role, Ronald is responsible for the overall oncology research strategy and pre-clinical development of novel drug candidates. Ronald joined MedImmune in February, 2006 as associate director of oncology research. Prior to MedImmune Ronald was Senior Principal Investigator in the Oncology Department at Schering-Plough Biopharma (formerly DNAX).
Dirk Jäger, MD
Dr. Jäger is the Director Medical Oncology, National Center for Tumor Diseases and University Medical Center Heidelberg.
Walter Kolch, MD, FRSE, MRIA
Walter Kolch is Director of Systems Biology Ireland, which was rated amongst the top 5 Systems Biology Institutes worldwide focussing on human disease in 2014.
Holger Moch, MD
Dr. Holger Moch is the Director, Medical Division Pathology and Laboratory Medicine at University Hospital in Zurich, Switzerland. He is also a Full Professor of Pathology at the University of Zurich and Chairman, Institute for Pathology, University Hospital Zurich, Switzerland.
Elfriede Nößner, PhD
Dr. Elfriede Nößner is a professor at the Ludwig-Maximilians-University of Munich (LMU) in Munich, Germany, and employed by the Helmholtz Zentrum Munich, where she is Head of the Immunoanalytics Research Group Tissue Control of Immunocytes and Core Facility. She also serves on the scientific advisory boards of Roche AG and AstraZeneca GmbH.